Rockbridge Investment Management, Lcc Alkermes Plc. Transaction History

Rockbridge Investment Management, Lcc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$23.37 - $28.68 $116 - $143	-5 Reduced 4.76%	100 $2.77 Million
Q3 2022 May 28, 2024	SELL	$22.0 - $31.87 $2,200 - $3,187	-100 Closed	0 $0
Q2 2022 May 28, 2024	SELL	$26.4 - $30.54 $132 - $152	-5 Reduced 4.76%	100 $2,000
Q1 2022 May 28, 2024	BUY	$23.07 - $27.99 $2,422 - $2,938	105 New	105 $2,000
Q2 2021 Aug 05, 2021	BUY	$18.78 - $25.15 $1,878 - $2,515	100 Added 2000.0%	105 $3,000
Q2 2020 Aug 20, 2020	BUY	$13.31 - $19.41 $66 - $97	5 New	5 $0

363

182M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.82B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Rockbridge Investment Management, Lcc, based on Form 13F filings with the SEC.

Stay updated on Rockbridge Investment Management, Lcc with notifications on news.